Liu X, Zhelev D, Adams C, Chen C, Mellors JW, Dimitrov DS. Effective killing of cells expressing
CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody.
Transl Oncol 2021;
14:101232. [PMID:
34601396 DOI:
10.1016/j.tranon.2021.101232]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 09/24/2021] [Indexed: 01/01/2023] Open
Abstract
A new fully human antibody, B11, that specifically targets CD276 was identified.
The epitope of B11 is the V1/V2 domain of CD276 and it competes with the antibody 8H9 (Omburtamab).
B11-BiTE mediates strong T cell cytotoxicity to 14 different tumor cell lines.
The pancaner molecule CD276 (B7-H3) is an attractive target for antibody based therapy. We identified from a large (1011) phage-displayed single-chain variable fragment (scFv) library, a fully human antibody, B11, which bound with high avidity (KD=0.4 nM) to CD276. B11 specifically bound to the V1/V2 domain of CD276 and competed with the antibody 8H9 (Omburtamab). It was used to design an IgG-format bispecific T cell engager B11-BiTE, which was more effective than 8H9-BiTE in 14 different cancer cell lines. B11-BiTE also exhibited strong ADCC/ADCP. Therefore, the fully human B11-BiTE is a promising candidate for treatment of tumors expressing CD276.
Collapse